DNA repair dysregulation from cancer driver to therapeutic target (Q38061847)

28 August 2017

1 reference

title

DNA repair dysregulation from cancer driver to therapeutic target (English)

1 reference

28 August 2017

Nicola J Curtin

1

1 reference

PubMed ID

23175119

28 August 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

28 August 2017

Nature Reviews Cancer

1 reference

28 August 2017

12

1 reference

28 August 2017

12

1 reference

28 August 2017

801-817

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3399

28 August 2017

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

31 March 2020

1 reference

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

31 March 2020

1 reference

DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy

31 March 2020

1 reference

Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential

31 March 2020

1 reference

Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy

31 March 2020

1 reference

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

31 March 2020

1 reference

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

31 March 2020

1 reference

Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib

31 March 2020

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

Instability and decay of the primary structure of DNA

31 March 2020

1 reference

Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine

31 March 2020

1 reference

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer

31 March 2020

1 reference

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

31 March 2020

1 reference

Poly(ADP-ribose): novel functions for an old molecule

31 March 2020

1 reference

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage

31 March 2020

1 reference

Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions

31 March 2020

1 reference

Organ and cell specificity of base excision repair mutants in mice

31 March 2020

1 reference

Is base excision repair a tumor suppressor mechanism?

31 March 2020

1 reference

Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer.

31 March 2020

1 reference

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

31 March 2020

1 reference

PARP inhibition: PARP1 and beyond

31 March 2020

1 reference

Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells

31 March 2020

1 reference

Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

31 March 2020

1 reference

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines

31 March 2020

1 reference

A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents

31 March 2020

1 reference

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

31 March 2020

1 reference

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

31 March 2020

1 reference

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

31 March 2020

1 reference

An upstream ORF with non-AUG start codon is translated in vivo but dispensable for translational control of GCN4 mRNA.

31 March 2020

1 reference

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

31 March 2020

1 reference

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

31 March 2020

1 reference

CS1-directed monoclonal antibody therapy for multiple myeloma

31 March 2020

1 reference

The xeroderma pigmentosum pathway: decision tree analysis of DNA quality

31 March 2020

1 reference

Nucleotide excision repair and its connection with cancer and ageing.

31 March 2020

1 reference

DNA repair capacity and cisplatin sensitivity of human testis tumour cells

31 March 2020

1 reference

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

31 March 2020

1 reference

DNA polymerases and cancer.

31 March 2020

1 reference

3-O-methylfunicone, a selective inhibitor of mammalian Y-family DNA polymerases from an Australian sea salt fungal strain

31 March 2020

1 reference

A real-time fluorescence method for enzymatic characterization of specialized human DNA polymerases

31 March 2020

1 reference

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

31 March 2020

1 reference

Causal link between microsatellite instability and hMRE11 dysfunction in human cancers

31 March 2020

1 reference

Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability

31 March 2020

1 reference

DNA damage tolerance, mismatch repair and genome instability

31 March 2020

1 reference

DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs

31 March 2020

1 reference

Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer

31 March 2020

1 reference

Regulation of DNA double-strand break repair pathway choice

31 March 2020

1 reference

Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining

31 March 2020

1 reference

ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2

31 March 2020

1 reference

DNA topoisomerase II, genotoxicity, and cancer

31 March 2020

1 reference

Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin

31 March 2020

1 reference

Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach

31 March 2020

1 reference

DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs

31 March 2020

1 reference

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

31 March 2020

1 reference

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K

31 March 2020

1 reference

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia

31 March 2020

1 reference

Cohesin: a regulator of genome integrity and gene expression

31 March 2020

1 reference

Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks

31 March 2020

1 reference

DNA interstrand crosslink repair and cancer

31 March 2020

1 reference

Targeting homologous recombination repair defects in cancer

31 March 2020

1 reference

A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex

31 March 2020

1 reference

Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells

31 March 2020

1 reference

Imatinib sensitizes CLL lymphocytes to chlorambucil

31 March 2020

1 reference

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

31 March 2020

1 reference

Multiple roles of ATM in monitoring and maintaining DNA integrity

31 March 2020

1 reference

Cell-cycle checkpoints and cancer

31 March 2020

1 reference

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

31 March 2020

1 reference

ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining

31 March 2020

1 reference

ATR: a master conductor of cellular responses to DNA replication stress

31 March 2020

1 reference

Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance

31 March 2020

1 reference

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

31 March 2020

1 reference

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

31 March 2020

1 reference

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

31 March 2020

1 reference

G1 cell-cycle control and cancer

31 March 2020

1 reference

Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints

31 March 2020

1 reference

ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation

31 March 2020

1 reference

Anticancer therapy with checkpoint inhibitors: what, where and when?

31 March 2020

1 reference

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

31 March 2020

1 reference

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

31 March 2020

1 reference

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

31 March 2020

1 reference

Targeting the S and G2 checkpoint to treat cancer.

31 March 2020

1 reference

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.

31 March 2020

1 reference

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

31 March 2020

1 reference

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

31 March 2020

1 reference

Integrating genetic approaches into the discovery of anticancer drugs

31 March 2020

1 reference

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

31 March 2020

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

31 March 2020

1 reference

Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

31 March 2020

1 reference

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

31 March 2020

1 reference

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

31 March 2020

1 reference

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

31 March 2020

1 reference

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors

31 March 2020

1 reference

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

31 March 2020

1 reference

Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.

31 March 2020

1 reference

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours

31 March 2020

1 reference

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

31 March 2020

1 reference

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors

31 March 2020

1 reference

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers

31 March 2020

1 reference

DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1

31 March 2020

1 reference

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

31 March 2020

1 reference

Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells

31 March 2020

1 reference

Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition

31 March 2020

1 reference

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated

31 March 2020

1 reference

CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors

31 March 2020

1 reference

Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner

31 March 2020

1 reference

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

31 March 2020

1 reference

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

31 March 2020

1 reference

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

31 March 2020

1 reference

Systematic identification of genomic markers of drug sensitivity in cancer cells

31 March 2020

1 reference

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

31 March 2020

1 reference

DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy

31 March 2020

1 reference

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

31 March 2020

1 reference

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

31 March 2020

1 reference

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers

31 March 2020

1 reference

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

31 March 2020

1 reference

DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells

31 March 2020

1 reference

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers

31 March 2020

1 reference

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies

31 March 2020

1 reference

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

31 March 2020

1 reference

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

31 March 2020

1 reference

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

31 March 2020

1 reference

Circulating tumour cells in cancer patients: challenges and perspectives

31 March 2020

1 reference

31 March 2020

1 reference

Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase

31 March 2020

1 reference

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

31 March 2020

1 reference

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

31 March 2020

1 reference

A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification

31 March 2020

1 reference

Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining

31 March 2020

1 reference

Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response

31 March 2020

1 reference

PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites

31 March 2020

1 reference

ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation

31 March 2020

1 reference

Purified human BRCA2 stimulates RAD51-mediated recombination

31 March 2020

1 reference

Targeted modulation of MGMT: clinical implications

31 March 2020

1 reference

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

31 March 2020

1 reference

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

31 March 2020

1 reference

DNA repair: from genome maintenance to biomarker and therapeutic target

31 March 2020

1 reference

NBS1 Heterozygosity and Cancer Risk

31 March 2020

1 reference

Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks

31 March 2020

1 reference

Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility

31 March 2020

1 reference

Human MRE11 is inactivated in mismatch repair-deficient cancers

31 March 2020

1 reference

Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks

31 March 2020

1 reference

Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity.

31 March 2020

1 reference

Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer

31 March 2020

1 reference

Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma

31 March 2020

1 reference

Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation

31 March 2020

1 reference

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program

31 March 2020

1 reference

Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines

31 March 2020

1 reference

Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability

31 March 2020

1 reference

Cancer incidence in persons with Fanconi anemia.

31 March 2020

1 reference

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

31 March 2020

1 reference

Cancer risks and mortality in heterozygous ATM mutation carriers

31 March 2020

1 reference

Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases

31 March 2020

1 reference

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

31 March 2020

1 reference

Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development

31 March 2020

1 reference

Inhibitors of DNA polymerase beta: activity and mechanism

31 March 2020

1 reference

Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair

31 March 2020

1 reference

Isolation of a small molecule inhibitor of DNA base excision repair.

31 March 2020

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

31 March 2020

1 reference

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

31 March 2020

1 reference

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

31 March 2020

1 reference

Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.

31 March 2020

1 reference

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab

31 March 2020

1 reference

Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks

31 March 2020

1 reference

SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization

31 March 2020

1 reference

Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening

31 March 2020

1 reference

Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation

31 March 2020

1 reference

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

31 March 2020

1 reference

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

31 March 2020

1 reference

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

31 March 2020

1 reference

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells

31 March 2020

1 reference

IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells

31 March 2020

1 reference

Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review

31 March 2020

1 reference

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

31 March 2020

1 reference

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.

31 March 2020

1 reference

12 December 2020

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers

1 reference

12 December 2020

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals

1 reference

12 December 2020

Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay

1 reference

12 December 2020

Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid - a mammalian DNA polymerase inhibitor.

1 reference

12 December 2020

Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents

1 reference

12 December 2020

Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

1 reference

12 December 2020

Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.

1 reference

12 December 2020

Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks

1 reference

12 December 2020

Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

1 reference

12 December 2020

Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon

1 reference

12 December 2020

Mechanisms of carcinogenesis induced by alkylating agents

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3399

1 reference

PubMed ID

23175119

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23175119